{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:39:50Z","timestamp":1787200790214,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s10741-005-2346-0","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T13:35:03Z","timestamp":1118324103000},"page":"31-37","source":"Crossref","is-referenced-by-count":91,"title":["Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation"],"prefix":"10.1007","volume":"10","author":[{"given":"Hylton V.","family":"Joffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail K.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"2346_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jcem-6-2-117","volume":"6","author":"H Selye","year":"1946","unstructured":"Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 1946;6:117\u2013230.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2346_CR2","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","volume":"88","author":"JS Williams","year":"2003","unstructured":"Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003;88(6):2364\u20132372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2346_CR3","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT, Jr., Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141(10):3871\u20133878.","journal-title":"Endocrinology"},{"issue":"20","key":"2346_CR4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.0000097000.51723.6F","volume":"108","author":"EM Oestreicher","year":"2003","unstructured":"Oestreicher EM, Martinez-Vasquez D, Stone JR, et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II\/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003;108(20):2517\u20132523.","journal-title":"Circulation"},{"issue":"12","key":"2346_CR5","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","volume":"143","author":"R Rocha","year":"2002","unstructured":"Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143(12):4828\u20134836.","journal-title":"Endocrinology"},{"issue":"5","key":"2346_CR6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63(5):1791\u20131800.","journal-title":"Kidney Int"},{"issue":"5","key":"2346_CR7","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283(5):H1802\u2013H1810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"2346_CR8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002;161(5):1773\u20131781.","journal-title":"Am J Pathol"},{"issue":"4 Pt 1","key":"2346_CR9","first-page":"E657","volume":"269","author":"M Young","year":"1995","unstructured":"Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269(4 Pt 1):E657\u2013E662.","journal-title":"Am J Physiol"},{"issue":"3","key":"2346_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/27.3.341","volume":"27","author":"KT Weber","year":"1993","unstructured":"Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27(3):341\u2013348.","journal-title":"Cardiovasc Res"},{"issue":"1 Pt 2","key":"2346_CR11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(1 Pt 2):451\u2013458.","journal-title":"Hypertension"},{"issue":"2 Part 2","key":"2346_CR12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","volume":"37","author":"A Fiebeler","year":"2001","unstructured":"Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001;37(2 Part 2):787\u2013793.","journal-title":"Hypertension"},{"issue":"10C","key":"2346_CR13","doi-asserted-by":"crossref","first-page":"40L","DOI":"10.1016\/S0002-9149(02)02963-6","volume":"90","author":"D Behrendt","year":"2002","unstructured":"Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002;90(10C):40L\u201348L.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2346_CR14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40(4):504\u2013510.","journal-title":"Hypertension"},{"issue":"2","key":"2346_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39(2):351\u2013358.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2346_CR16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105(18):2212\u20132216.","journal-title":"Circulation"},{"issue":"6","key":"2346_CR17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","volume":"41","author":"S Keidar","year":"2003","unstructured":"Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003;41(6):955\u2013963.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"18","key":"2346_CR18","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","volume":"109","author":"S Keidar","year":"2004","unstructured":"Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109(18):2213\u20132220.","journal-title":"Circulation"},{"issue":"2","key":"2346_CR19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000111138.78714.1a","volume":"43","author":"S Arima","year":"2004","unstructured":"Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004;43(2):352\u2013357.","journal-title":"Hypertension"},{"issue":"2 Pt 2","key":"2346_CR20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","volume":"39","author":"DV Martinez","year":"2002","unstructured":"Martinez DV, Rocha R, Matsumura M, et al. Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading. Hypertension 2002;39(2 Pt 2):614\u2013618.","journal-title":"Hypertension"},{"issue":"10","key":"2346_CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709\u2013717.","journal-title":"N Engl J Med"},{"issue":"15","key":"2346_CR22","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003;108(15):1831\u20131838.","journal-title":"Circulation"},{"issue":"5","key":"2346_CR23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41(5):1021\u20131026.","journal-title":"Hypertension"},{"issue":"5","key":"2346_CR24","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI118312","volume":"96","author":"DM Kerins","year":"1995","unstructured":"Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96(5):2515\u20132520.","journal-title":"J Clin Invest"},{"issue":"1","key":"2346_CR25","first-page":"336","volume":"85","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85(1):336\u2013344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"2346_CR26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","volume":"342","author":"HP Kohler","year":"2000","unstructured":"Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342(24):1792\u20131801.","journal-title":"N Engl J Med"},{"issue":"1","key":"2346_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/jmcc.1999.1053","volume":"32","author":"M Katoh","year":"2000","unstructured":"Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000;32(1):73\u201383.","journal-title":"J Mol Cell Cardiol"},{"issue":"Suppl 2","key":"2346_CR28","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.jhh.1001392","volume":"16","author":"I Gavras","year":"2002","unstructured":"Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 2002;16(Suppl 2): S2\u2013S6.","journal-title":"J Hum Hypertens"},{"issue":"9A","key":"2346_CR29","doi-asserted-by":"crossref","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","volume":"88","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(9A):1L\u201320L.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2346_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","volume":"33","author":"M Nishimura","year":"1999","unstructured":"Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999;33(2):261\u2013266.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2346_CR31","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","volume":"95","author":"GP Rossi","year":"1997","unstructured":"Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma. Circulation 1997;95(6):1471\u20131478.","journal-title":"Circulation"},{"issue":"12 Pt 2","key":"2346_CR32","first-page":"1801","volume":"13","author":"JM Halimi","year":"1995","unstructured":"Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995;13(12 Pt 2):1801\u20131802.","journal-title":"J Hypertens"},{"issue":"5","key":"2346_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27(5):1039\u20131045.","journal-title":"Hypertension"},{"issue":"14","key":"2346_CR34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309\u20131321.","journal-title":"N Engl J Med"},{"issue":"4 (Part 2)","key":"2346_CR35","doi-asserted-by":"crossref","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02330-0","volume":"15","author":"E Burgess","year":"2002","unstructured":"Burgess E, Niegowksa J, Tan KW, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension. Amer J Hypert 2002;15(4 (Part 2)): 23A.","journal-title":"Amer J Hypert"},{"issue":"12","key":"2346_CR36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001;345(12):925\u2013926.","journal-title":"N Engl J Med"},{"issue":"4 (Part 2)","key":"2346_CR37","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew JV, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Amer J Hypert 2002;15(4 (Part 2)):24A.","journal-title":"Amer J Hypert"},{"issue":"1","key":"2346_CR38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64\u201368.","journal-title":"Hypertension"},{"issue":"4","key":"2346_CR39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy.Clin Sci (Lond) 2002;103(4):425\u2013431.","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"2346_CR40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101(6):594\u2013597.","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-2346-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-005-2346-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-2346-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:01:13Z","timestamp":1559242873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-005-2346-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["2346"],"URL":"https:\/\/doi.org\/10.1007\/s10741-005-2346-0","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}